Zevra Therapeutics (ZVRA) Cash from Operations Growth (5y) (2019 - 2026)

Zevra Therapeutics (ZVRA) Cash from Operations Growth (5y) (2019 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Zevra Therapeutics 570.04 Mn 369.43 Mn 34.32 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 34.34%
Dec 31, 2025 48.45%
Sep 30, 2025 45.32%
Jun 30, 2025 -29.50%
Mar 31, 2025 -32.39%
Dec 31, 2024 -39.30%
Sep 30, 2024 -52.09%
Jun 30, 2024 -21.08%
Mar 31, 2024 -7.87%
Dec 31, 2023 -1.50%
Sep 30, 2023 21.93%
Jun 30, 2023 1.00%
Mar 31, 2023 22.10%
Dec 31, 2022 8.44%
Sep 30, 2022 8.29%
Jun 30, 2022 8.71%
Mar 31, 2022 17.89%
Dec 31, 2021 38.14%
Sep 30, 2021 19.89%
Jun 30, 2021 31.99%